comscoreDoes Chemotherapy Choice Affect How Well Tecentriq Works Against Breast Cancer?

Does Chemotherapy Choice Affect How Well Tecentriq Works Against Breast Cancer?

Dr. Leisha Emens explains two recent studies of Tecentriq, their differences, and what it means for patients.
Oct 23, 2020
00:00
Download
00:00

At the European Society for Medical Oncology Virtual Congress 2020, Dr. Emens presented final overall survival results from the IMpassion130 study, showing that the combination of Tecentriq, which has the chemical name atezolizumab, and Abraxane, which has the chemical name nab-paclitaxel, improved overall survival by 7.5 months compared to Abraxane alone for people diagnosed with metastatic PD-L1-positive, triple-negative breast cancer. But another trial — the IMpassion131 study — found that combining Tecentriq with Taxol, a different form of paclitaxel, was no better than Taxol alone in treating the same type of breast cancer — metastatic triple-negative disease.

Listen to the podcast to hear Dr. Emens explain:

  • the differences in the designs of the two studies

  • how Abraxane is different from Taxol

  • possible reasons for the difference in results

  • what this means for patients

About the guest
 
Leisha Emens headshot
Leisha Emens, MD, PhD

Dr. Leisha Emens is a professor of medicine in hematology/oncology at the University of Pittsburgh Medical Center Hillman Cancer Center. She is also co-leader of the Hillman Cancer Immunology and Immunotherapy Program, and director of translational immunotherapy for the Women's Cancer Research Center. Dr. Emens specializes in cancer immunotherapy, and her research focuses on the development and implementation of breast cancer immunotherapies (including vaccines and immune checkpoint inhibitors) in combination with traditional cancer treatments and other drugs that activate the immune system. Dr. Emens discloses that she has received research support from Merck, EMD-Serono, AstraZeneca, Genentech-Roche, Corvus, and Aduro. She has received honoraria from Vaccinex, Amgen, Syndax, Peregrine, Bayer, and Gritstone.

— Last updated on June 29, 2022, 2:46 PM

 
Lilly

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate